HC Wainwright Reiterates Buy Rating on RGNX
HC Wainwright reaffirms its positive outlook on RGNX, maintaining a buy rating and a $26 price target, a 150.24% upside from the current price.
Key Points
- HC Wainwright reaffirmed its buy rating on RGNX, setting a $26 price target as of June 24, 2026.
- HC Wainwright's $26 price target implies 150.24% upside from REGENXBIO Inc.'s ($RGNX) current $10.39 share price.
- RGNX shares traded near $9.97 on Friday, with a market cap of approximately $529.4 million.
- Insiders like Kenneth Mills and Daniel Tasse purchased shares recently, while major funds like BlackRock adjusted their holdings.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
On June 24, 2026, HC Wainwright reiterated its buy rating on RGNX, setting a price target of $26. Analyst Yi Chen expressed confidence in the stock, which traded near $9.97 on Friday.
HC Wainwright & Co. vs. the S&P 500
Hypothetical, simulated performance of disclosed positions vs. the S&P 500. Not realized profit and not investment advice. Past performance does not indicate future results. Details.
Other Institutional Activity in RGNX
Several major funds have been adjusting their positions in RGNX. BlackRock, Inc. increased its holdings by 25,997 shares, ending with 5,782,808 shares valued at about $48.5 million. Redmile Group, LLC maintained its position with 4,368,804 shares worth $36.6 million. JPMorgan Chase & Co. reduced its stake by 69,702 shares, holding 3,483,800 shares valued at $27.1 million. State Street Corp significantly boosted its holdings by 444,749 shares to 2,731,485 shares, valued at $22.9 million. Vanguard Capital Management LLC opened a new position with 2,007,146 shares worth $16.8 million.
REGENXBIO Inc. Stock Up 7.6%
Shares of RGNX traded near $9.97 on Friday. The company has a market capitalization of approximately $529.4 million. The stock's performance over the past year has seen a 52-week range between $5.50 and $15.00.
$RGNX price target
Past daily closes and this analyst's 12-month price target. Not investment advice.
Insider Buying and Selling at REGENXBIO Inc.
Several insiders made notable purchases on May 29, 2026. Kenneth Mills, Daniel Tasse, and David Stump each bought 46,600 shares. Additionally, Kenneth Mills, Allan Fox, and Alexandra Glucksmann each acquired 9,807 shares. These transactions were not part of a pre-planned trading program.
Analysts Set New Price Targets
On June 24, 2026, HC Wainwright & Co. reiterated its buy rating on RGNX with a $26 price target. Earlier, on June 22, 2026, Baird maintained its buy rating with a $32 target, and Leerink Partners held a buy rating with an $18 target. Overall, analysts maintain a positive outlook on RGNX, with a consensus buy rating and an average price target reflecting optimism about the stock's future performance.
About RGNX
RGNX operates in the biotechnology sector, focusing on developing gene therapy products for the treatment of genetic disorders. The company is headquartered in Maryland and works on innovative therapies to address unmet medical needs. RGNX employs a team of dedicated scientists and researchers committed to advancing healthcare solutions.
Bottom Line
HC Wainwright's reaffirmation of a buy rating with a $26 target highlights continued confidence in RGNX's potential. Investors closely monitor such analyst updates for insight into the stock's prospects. Note that these ratings are based on past data and may not reflect current conditions.
Get REGENXBIO Inc. alerts
New 13F filings, insider trades, and analyst moves on $RGNX, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.